News

Cassiopea SpA and Sun Pharma announce that Sun Pharma will commercialise Winlevi, a treatment for acne, in the US and Canada.

Read time: 1 mins

Published:1st Sep 2021

Cassiopea SpA and Sun Pharmaceutical Industries Ltd have .announced the expiration of the applicable waiting period under the US Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the exclusive License and Supply Agreements signed by both companies for Winlevi (clascoterone cream 1%), The agreements are effective as of August 31, 2021.

Sun Pharma now has the exclusive right to commercialize Winlevi in the United States and Canada. Cassiopea will be the exclusive supplier of the product. Winlevi is expected to be available in the U.S. in Q4 2021.

Condition: Acne

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Cidara Therapeutics reacquires global development and commercial rights to CD 388

Cidara Therapeutics, Inc. a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced that it has entered into a definitive agreement with Johnson & Johnsonto reacquire the exclusive global development and commercial rights to CD 388, which is in development for the prevention of all strains of influenza A and B

1 mins

Drug news

Cidara Therapeutics announces the divestiture of rezafungin rights to MundiPharma

Cidara Therapeutics, Inc. announced that it has entered into an asset purchase agreement with its current partner, Mundipharma, for the divestiture of rezafungin

1 min

Drug news

FINTEPLA (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Fintpla (fenfluramine) oral solution has been approved by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older

1 min

See all news